白蛋白结合型紫杉醇联合放疗对非小细胞肺癌伴上腔静脉压迫综合征的疗效  

Efficacy of Albumin-Bound Paclitaxel Combined With Radiotherapy in Non-Small Cell Lung Cancer With Superior Vena Cava Syndrome

作　　者：赵善琳 原浩 韦燕 曾伟明 黄店 冯荣浩 潘琦津 ZHAO Shanlin;YUAN Hao;WEI Yan;ZENG Weiming;HUANG Dian;FENG Ronghao;PAN Qijin(Department of Oncology,the Eighth Affiliated Hospital of Guangxi Medical University/Guigang City People's Hospital,Guigang Guangxi 537100,China)

机构地区：[1]广西医科大学第八附属医院/贵港市人民医院肿瘤科,广西贵港537100

出　　处：《中国卫生标准管理》2024年第20期156-160,共5页China Health Standard Management

摘　　要：目的分析白蛋白结合型紫杉醇联合放疗对非小细胞肺癌(non-small cell lung cancer,NSCLC)伴上腔静脉压迫综合征(superior vena cava syndrome,SVCS)的疗效。方法回顾性分析2019年1月—2022年1月广西医科大学第八附属医院收治的使用白蛋白结合型紫杉醇同期联合放疗的28例NSCLC伴SVCS患者临床资料。分析28例患者的近期疗效、生存时间及不良反应。结果28例NSCLC伴SVCS患者中,客观缓解率(objective response rate,ORR)为71.43%,疾病控制率(disease control rate,DCR)为89.29%,中位无进展生存时间3.30个月(95%CI 2.56~4.04个月),中位生存时间为7.20个月(95%CI 6.44~7.98个月)。化疗线数、T分期是影响患者中位无进展生存期(progression-free survival,PFS)的独立危险因素(P<0.05);化疗线数和N分期是影响总生存期(overall survival,OS)的独立危险因素(P<0.05);不良反应有血液学反应、胃肠道、关节及外周神经毒性、肝肾功能损害及放射急性反应。结论白蛋白结合型紫杉醇联合放疗对NSCLC伴SVCS患者有较好的客观疗效,安全性良好;T分期≤3、N分期<2的患者在治疗中可能获益更大。Objective To analyze the efficacy of albumin-bound paclitaxel combined with radiotherapy for non-small cell lung cancer(NSCLC)with superior vena cava syndrome(SVCS).Methods The clinical data of 28 patients with NSCLC with SVCS treated with albumin-bound paclitaxel combined with radiotherapy during the same period in the Eighth Affiliated Hospital of Guangxi Medical University from January 2019 to January 2022 were retrospectively analyzed.Recent efficacy,survival time and adverse effects of 28 patients were analyzed.Results Among 28 patients with NSCLC and SVCS,the objective response rate(ORR)was 71.43%,disease control rate(DCR)was 89.29%,median progression-free survival time was 3.30 months(95%CI 2.56 to 4.04 months)and median survival time was 7.20 months(95%CI 6.44 to 7.98 months).The number of chemotherapy lines and T stage are independent risk factors affecting progression-free survival(PFS)(P<0.05).The number of chemotherapy lines and N stage are independent risk factors affecting overall survival(OS)(P<0.05).Adverse reactions include hematologic reaction,gastrointestinal,joint and peripheral neurotoxicity,hepatic and renal function impairment and acute radiation reaction.Conclusion Albumin-bound paclitaxel combined with radiotherapy has good objective efficacy and safety in patients with NSCLC with SVCS;patients with T stage≤3 and N stage<2 may benefit more from treatment.

关 键 词：上腔静脉压迫综合征 放射治疗 白蛋白结合型紫杉醇 化疗 肺癌 同步放疗 

分 类 号：R734[医药卫生—肿瘤]